Comparison 7. Bexarotene high versus low dose.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
7.1 Common adverse effects	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
7.1.1 Photosensitivity	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
7.1.2 Nausea	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
7.1.3 Constipation	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
7.1.4 Fatigue	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
7.1.5 Pruritus	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
7.1.6 Arthralgia	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
7.1.7 Nasopharyngitis	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
7.1.8 Headache	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
7.1.9 Insomnia	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
7.1.10 Free T4 abnormalities	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
7.1.11 Cholesterol abnormalities	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
7.1.12 Triglycerid abnormalities	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
7.1.13 SGOT/SGPT abnormalities	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
7.2 Complete response	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
7.3 Relapse	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
7.4 Objective response rate	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only